Top Story

Bone Therapeutics to expand into cell-matrix offerings

February 1, 2015

Bone Therapeutics recently announced it will undertake efforts to expand its offerings to include osteoblastic cell-matrix products.
These offerings, which will be used to treat large bone defects, will be a variant of the company’s osteoblastic cells within a 3-D bioprinted scaffold. The company believes this will become a favorable alternative to the current standard of care, bone autograft, according to a press release.

The company’s venture has been met with support from the government of the Walloon region, which has given Bone Therapeutics €1 million in non-dilutive, recoverable cash advances to finance the company’s efforts.

Integra LifeSciences acquires multiple product lines from Metasurg

January 31, 2015
Integra LifeSciences recently announced the acquisition of biologics and foot and ankle product offerings from Metasurg.The transactions, which closed in December, will…
In the Journals

More sensitivity, specificity seen with preoperative synovial fluid IL-6 measurement

January 30, 2015
For patients who underwent revision shoulder arthroplasty, preoperative measurement of synovial fluid interleukin-6 levels was more sensitive and specific compared with…
In the Journals

Similar short-term outcomes seen in robot-assisted, conventional TKA

January 30, 2015
Similar short-term clinical outcomes, such as reduction of mechanical axis alignment and joint-line deviation outliers, were found among patients who underwent…
In the Journals

Navigated, non-navigated kyphoplasty appears to produce similar outcomes

January 30, 2015
Compared with non-navigational kyphoplasty procedures, intraoperative 3-D image-based navigation kyphoplasty outcomes were not significantly improved, according to data…
More News Headlines »
Feature Article

Long-term Results of Shoulder Hemiarthroplasty in Patients With Rheumatoid Arthritis

Orthopedics, January 2015, Volume 38 Issue 1
Rheumatoid arthritis affecting the shoulder is typically associated with destruction of the glenohumeral joint and…
More »
No Decreased Infection Rate When Using Antibiotic Impregnated Cement in Primary TJA

No Decreased Infection Rate When Using Antibiotic Impregnated Cement in Primary TJA

There has been much debate and controversy about the routine use of antibiotic-impregnated bone cement in…
More »
Meeting News Coverage Video
thumbnail for video 4006885392001

Larson discusses autograft selection

January 23, 2015
KOLOA, Hawaii – At Orthopedics Today Hawaii 2015, Christopher M. Larson, MD, shares his “pearls” for…
More »